Phenylpiracetam

Phenylpiracetam (fonturacetam, INN; carphedon; 4-phenylpiracetam) is a racetam-class nootropic and psychostimulant first described by Bobkov et al. in 1983 and developed at the Institute of Biomedical Problems of the Russian Academy of Sciences for the enhancement of cognitive, physical, and thermoregulatory performance in cosmonauts operating under conditions of sustained stress, microgravity, and cold exposure. The compound is the 4-phenyl-substituted analog of piracetam and was approved for medical use in Russia in 2003 under the trade name Phenotropil for indications including cerebrovascular insufficiency, cognitive decline following stroke or traumatic brain injury, depression, asthenia, and attentional disorders. Phenylpiracetam is approximately 20- to 60-fold more potent than piracetam in animal models of cognition and anticonvulsant activity, an enhancement attributed to the phenyl substituent conferring increased lipophilicity, improved blood-brain barrier penetration, and direct engagement with monoaminergic and glutamatergic receptor systems that the parent compound does not meaningfully occupy. The molecular pharmacology of phenylpiracetam has been substantially clarified by the work of Zvejniece, Dambrova, and colleagues at the Latvian Institute of Organic Synthesis, who demonstrated in 2011 that the racemic compound binds the alpha-4-beta-2 subtype of the nicotinic acetylcholine receptor with an IC50 of 5.86 micromolar, and in 2017 that the individual enantiomers exhibit divergent dopamine transporter (DAT) pharmacology: (R)-phenylpiracetam is a dual norepinephrine-dopamine reuptake inhibitor with an IC50 at DAT of approximately 14.5 micromolar and 11-fold lower affinity for the norepinephrine transporter, while (S)-phenylpiracetam is a selective DAT inhibitor that reduces body weight gain in obese Zucker rats and diet-induced obesity models without producing the locomotor stimulation characteristic of the (R)-enantiomer [1, 2]. The (R)-enantiomer is the more pharmacologically active form for psychostimulant and procognitive effects and is the subject of independent patent filings for Parkinson disease, sleep disorders, and disease-associated fatigue. Both enantiomers additionally modulate AMPA-type glutamate receptors through positive allosteric modulation, consistent with the broader racetam class mechanism, and contribute to neuroprotective and anti-inflammatory activity demonstrated in lipopolysaccharide and carrageenan inflammation models [3]. Pharmacokinetics in humans are characterized by rapid oral absorption with near-complete bioavailability, a time to maximum plasma concentration of approximately one hour, a plasma elimination half-life of three to five hours, and negligible hepatic metabolism: the compound is excreted essentially unchanged, with approximately 40 percent recovered in urine and 60 percent in bile and sweat. The absence of cytochrome P450 involvement eliminates the polymorphic pharmacokinetic variability that complicates other nootropic and psychostimulant agents and reduces drug-drug interaction liability. Clinical evidence is derived predominantly from Russian-language trials of moderate methodological rigor. A 12-month study in approximately 400 post-stroke patients demonstrated enhanced recovery of neurological function and cognitive performance relative to standard rehabilitation. A 30-day trial in 99 patients with cognitive deficits secondary to surgery or traumatic brain injury reported significant improvements in motor coordination, memory, attention, and higher brain function at 200 mg daily. An adjunctive epilepsy trial reported seizure frequency reduction and cognitive benefit. The compound has been on the World Anti-Doping Agency Prohibited List since 1998 as a stimulant (class S6), following detection in athlete doping control samples at the 1997 World Athletics Championships. This monograph reviews the chemistry, synthesis, and stereochemistry of phenylpiracetam; the dopaminergic, nicotinic, and glutamatergic receptor pharmacology with enantiomer-resolved detail; human pharmacokinetics; the preclinical and clinical evidence base across cognitive, neuroprotective, anti-inflammatory, metabolic, and physical performance domains; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; adverse-event and safety signal; and a comparative assessment of five alternative nootropic and procognitive compounds against phenylpiracetam on five competency standards.